LOC729942 Inhibitors

Wortmannin and LY294002, both PI3K inhibitors, can suppress the PI3K/AKT signaling axis, which is central to many cellular processes, including cell survival and metabolism. By inhibiting this pathway, these compounds can regulate proteins that are downstream of PI3K/AKT. Rapamycin and Temsirolimus, as mTOR inhibitors, can alter the activity of proteins involved in cell growth and proliferation that are regulated by the mTOR pathway. Trametinib, a MEK inhibitor, and Sorafenib, a multi-kinase inhibitor, can modify the MAPK/ERK pathway and other kinases, leading to altered protein activity within these networks.

Dasatinib and AZD0530 are Src kinase inhibitors, and their action can affect the Src signaling pathway, potentially influencing related proteins, while Palbociclib, by inhibiting CDK4/6, interrupts cell cycle progression, which can affect proteins associated with this process. Imatinib, with its ability to inhibit BCR-ABL, PDGFR, and c-kit, and Sunitinib, a multi-receptor tyrosine kinase inhibitor, both lead to modifications in cellular signaling that can regulate various proteins. Lastly, Bortezomib disrupts the proteasome pathway, thereby potentially altering the degradation and turnover of specific proteins, including those associated with the ubiquitin-proteasome pathway.